

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number
WO 2005/018652 A1

(51) International Patent Classification⁷: **A61K 33/34**,
A23L 1/302, C07G 13/00, B65D 75/36, A61P 3/02, A61K
45/06

(74) Agents: DUBUC, J. et al.; Goudreau Gage Dubuc, Stock
Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box
242, Montreal, Quebec H4Z 1E9 (CA).

(21) International Application Number:
PCT/CA2004/001533

(22) International Filing Date: 20 August 2004 (20.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,438,043 21 August 2003 (21.08.2003) CA
2,438,155 21 August 2003 (21.08.2003) CA

(71) Applicant (for all designated States except US): DUCH-
ESNAY INC. [CA/CA]; 2925, Boul. Industriel, Laval,
Quebec H7L 3W9 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GERVAIS, Eric
[CA/CA]; 2526, des Oiseaux, Laval, Quebec H7L 4W9
(CA). ATANACKOVIC, Gordana [CA/CA]; 10 Green-
ing Crescent, Toronto M9A 1N8 (CA). BOIVIN, Pierre
[CA/CA]; 2350 Place des Flamants, Laval, Quebec H7L
4C1 (CA).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

[Continued on next page]

(54) Title: MICRONUTRIENT SUPPLEMENT



(57) Abstract: A micronutrient supplement the supplement being characterized by having at least two types of distinct dosage units wherein said distinct dosage units which physically separate nutritional, vitamin or mineral supplements which are known or proven to be negatively interacting when co-mingled or co-administered, the distinct dosage units being designed to be taken at a predetermined time interval.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

TITLE OF THE INVENTION

MICRONUTRIENT SUPPLEMENT

FIELD OF THE INVENTION

[0001] The present invention relates to a micronutrient supplement
5 containing ingredients such as multivitamins, minerals, fatty acids, amino acids,
plant extracts, and the like.

BACKGROUND OF THE INVENTION

[0002] Micronutrient compositions are commonly taken as dietary
aids; either as therapeutic preparations directed to a specific medical problem
10 or as general nutritional supplements. Micronutrients may be broadly defined
as substances that are essential or helpful for the maintenance of normal or
enhanced metabolic function, but are not normally or sufficiently synthesized in
the body and must thus be supplied from an exogenous source.

[0003] Given poor dietary habits of individuals and other factors, it
15 has become clear that the role of micronutrient compositions is substantial
when it comes to preventing fatigue, disease and optimizing cell maintenance
and development. This is particularly the case for individuals who lead a
stressful lifestyle, for pregnant women or those who engage in a large amount
of physical exercise. Additionally, many drugs, some chronic diseases (e.g.
20 rheumatoid arthritis), certain cancer treatments, and alcoholism can all lead to
a deficiency in one or more micronutrients.

[0004] It is has also been suggested that a significant portion of
preventable illnesses (which it is estimated absorbs as much as 70 per cent of

total health care costs in the United States) could be readily prevented through supplementing the diet with micronutrients. In addition to major health care cost savings other benefits of supplementation include better quality of life, longer life, and increased productivity. The level of supplements required for effective
5 disease protection cannot be obtained through even the most healthful diet (Bendich, Adrienne, et al. *Potential health economic benefits of vitamin supplementation*. Western Journal of Medicine, Vol. 166, May 1997, pp. 306-12).

[0005] Micronutrients are especially important to pregnant or
10 lactating women, ensuring an adequate provision of nutrients for the developing fetus and for the mother. It has become clear that the role of micronutrients is substantial when it comes to preventing fatigue, disease and optimizing cell maintenance and development.

[0006] Many micronutrient supplements however, pose a potential
15 problem of nutrient-nutrient interactions. The presence or excess of one nutrient in such a supplement may interact with another nutrient, thereby adversely affecting its absorption. Iron for example is reported to inhibit the co-absorption of zinc and vice-versa (Hambridge et al., *Obstet. Gynecol.* 4:593-596, 1987); zinc is reported to inhibit the co-absorption of copper (Festa et al.,
20 *Am.J. Clin. Nutr.* 41:285-292, 1985); calcium is reported to interfere with the co-absorption of both iron and zinc (Seligman et al., *Obstet. Gynecol.* 61:356-362, 1983); and protein supplements are reported to increase urinary calcium losses (Allen et al., *Am.J. Clin. Nutr.* 32: 741-749. 1979) and to increase vitamin B₆ requirements (*National Research Council, Recommended Dietary Allowances*,
25 10th ed., Natl. Acad. Press, Washington, D.C. 1989). Iron and copper are also known to degrade folic acid and vitamin B12 when commingled.

[0007] Prior art efforts at multivitamins and nutritional aids have often circumvented this problem by using greater doses of ill-absorbed or degraded nutrients. Indeed, there has been a trend towards using mega doses of many nutrients. Such practice is a risky one since an overdose of many nutrients, in particular metallic compounds, can be toxic, thereby achieving the opposite result of creating sickness rather than preventing it. One notable example is iron.

[0008] Iron-deficiency anemia is a primary risk during pregnancy because of the increasing red blood cell mass of the mother, the demands of the fetus and placenta (more so in the second and third trimesters of pregnancy), and blood losses during childbirth. Thus, prevention of iron deficiency is of prime importance. A common problem with prior art supplements is that little of the iron ingredients is actually absorbed in the blood stream. The known way to deal with this is to use larger doses of iron ingredients which in turn triggers constipation, nausea when taken on an empty stomach and a metallic taste (Solvell L.; *Oral iron therapy: Side effects. In Iron Deficiency: Pathogenesis, Clinical Aspects, Therapy* Edited by L Hallberg, HG Harwerth and A Vannotti: London, Academic Press, 1970, pp. 573-583).

[0009] Another important micronutrient is folic acid. Studies have revealed that folic acid may play an important role in preventing some types of cancers (e.g. Stolzenberg-Solomon, Rachael Z., et al. *Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers*. American Journal of Epidemiology, Vol. 153, April 1, 2001, pp. 680-87), heart disease (Loria, Catherine M., et al. *Serum folate and cardiovascular disease mortality among US men and women*. Archives of Internal Medicine, Vol. 160, November 27, 2000, pp. 3258-62.), and depression (Alpert, Jonathan E. and Fava, Maurizio. *Nutrition and depression: the role of folate*. Nutrition

Reviews, Vol. 55, May 1997, pp. 145-49). It is also well established that taking folic acid before and during pregnancy as a nutritional supplement greatly reduces risks of fetal diseases such as spina-bifida or cleft lip and palate. If use of the supplement containing folic acid is discontinued because of iron
5 intolerance, the benefits of the folic acid will be lost.

[0010] Thus, the importance of many of the ingredients present in micronutrient supplements may not be overstated.

[0011] In the prior art, U.S. Patent No. 5,932,624, discloses vitamin supplements comprising folic acid and vitamin B₁₂, and which are essentially
10 free of antioxidants such as phytochemicals, certain vitamins, and minerals such as iron and copper, which are known to destroy some of the vitamin B₁₂ and folic acid. However, such vitamin supplement, in an effort to avoid co-absorption problems provides an incomplete product, which fails to include important components such as iron and copper.

15 **[0012]** U.S. Patent No. 5,976,568 provides examples of various multivitamins some of them to be taken twice a day. However, the ingredients of the morning and evening tablets are identical. The apparent purpose of the twice-a-day formulation is to provide a second dose of ingredients, which may have been used up during the day. Another drawback of the multivitamin
20 compositions proposed in this prior art is the presence of many competing nutrients in a single dosage unit, e.g. iron, calcium and zinc.

[0013] Other problems often associated with patient non-compliance with recommended use of multivitamins and nutritional supplements are related to the large size of the tablets. For example, in the case of pregnant women,
25 because pregnant women are sometimes nauseated and because of their

normal instinct to avoid pharmaceutical products, the size and appearance of current products is often enough to cause a pregnant woman to discontinue taking the multivitamin or nutritional aid.

[0014] Published Canadian patent application No. 2,258,868
5 discloses an attempt at creating a slightly smaller tablet. The tablet composition is said to provide high levels of calcium (calcium citrate) and iron (carbonyl iron) while maintaining a smaller than usual size. Calcium citrate is described as enhancing the absorption of iron, zinc and magnesium, and as being more soluble, better absorbed and better tolerated than traditional
10 calcium supplements. Carbonyl iron on the other hand, is described as having a higher iron content as compared to the ferrous salts. The use of Ultradense™ calcium citrate and carbonyl iron allows the formulation to be compressed into acceptably sized tablets.

[0015] Canadian patent application No. 2,144,751 and U.S. Patent
15 No. 5,494,678, discloses a multivitamin and mineral supplement for pregnant women. The iron component is said to be ferrous sulfate, coated with a pharmaceutically acceptable film forming material. The coating is said to provide for the release of the ferrous sulfate in the intestine, thus apparently minimizing interactions between iron and divalent cations such as calcium (also
20 in the supplement), in turn improving the iron bioavailability. Thus, the co-absorption problem is dealt with by suggesting that absorption of various components should be engineered to occur at different body sites.

[0016] U.S. Patent No. 4,431,634 discloses multi-mineral prenatal dietary supplements, said to maximize the bioavailability of iron. This is
25 apparently accomplished by maintaining the amount of calcium compounds in

the supplement at 300 mg or less, and the amount of magnesium compounds at 75 mg or less, per dosage unit.

[0017] Despite the foregoing efforts to improve micronutrient supplements, there remains a need to develop micronutrient compositions
5 overcoming the drawbacks of prior art compositions.

[0018] The micronutrient supplement of the present invention seeks to avoid deleterious co-absorption problems associated with co-mingled ingredients.

[0019] The micronutrient supplement of the present invention also
10 seeks to provide rather small and palatable dosage units when compared to those of the prior art.

[0020] In a preferred embodiment, the micronutrient supplement of the present invention provides optimal nutritional components and amounts that have been found to benefit both fetal growth and the mother's health
15 throughout the pregnancy.

[0021] The micronutrient supplement of the present invention also allows the presentation of the tablet ingredients in the form of a plurality of different dosage units so that a patient can voluntarily take some ingredients and not others in case they suffer from intolerance or side effects caused by
20 specific ingredients such as iron.

[0022] The present invention seeks to meet these and other needs.

[0023] The words "a" and "an," as used in this specification, including the claims, denote "one or more." Specifically, the use of "comprising," "having," or other open language in claims that claim a combination or method employing "an object," denotes that "one or more of the
5 object" may be employed in the claimed method or combination.

SUMMARY OF THE INVENTION

[0024] In general terms, the present invention provides a micronutrient supplement, the supplement being characterized by having at least two types of dosage units designed to be taken at a predetermined time
10 interval.

[0025] In a preferred embodiment, micronutrients such as vitamin and mineral supplements which are known or proven to be absorption-competing when co-administered are thus be prepared as separate and distinct dosage units and are administered at spaced time intervals so as to minimize
15 drop-offs in absorption and co-absorption problems.

[0026] Still in a preferred embodiment, micronutrients such as vitamin and mineral supplements, which are known to potentially cause deleterious side effects, for example constipation in the case of iron supplements, can be grouped in a separate and distinct dosage unit. Therefore,
20 by virtue of the present invention a patient may temporarily stop taking a type of dosage unit of the invention and continue to take the other dosage unit(s) of the invention. The overall effect is to avoid discontinuing the use of supplements entirely and thereby avoiding discontinuance of important ingredients unrelated to the side effects of some ingredients.

[0027] Still in a preferred embodiment, the micronutrient supplement is destined for pregnant women and provides optional nutritional components and amounts that have been found to benefit both fetal growth and the mother's health before, throughout and after pregnancy (post-partum).

- 5 **[0028]** The present invention also provides a micronutrient supplement in the form of a kit comprising a plurality of types of dosage units along with instructions for taking the dosage units at spaced time intervals.

BRIEF DESCRIPTION OF THE DRAWINGS

- [0029]** Having thus generally described the invention, reference will
10 now be made to the accompanying drawings, showing by way of illustration a preferred embodiment thereof, and in which:

- [0030]** Figure 1 shows a perspective view of an example of a kit of the present invention and more specifically an individual blister pack of a week's worth of the supplement of the present invention having an array of a
15 first type of dosage unit to be taken at a given time of day and an array of a second type of dosage unit to be taken at another time of day.

DESCRIPTION OF THE PREFERRED EMBODIMENT

[0031] The present invention will now be described by means of an illustrative and preferred embodiment.

- 20 **[0032]** In a most preferred embodiment, the invention discloses a micronutrient supplement in the form of two distinct dosage units to be taken at

spaced time intervals. Ideally, the time interval will be 12 hours, however, the time interval may be as short as 4 hours.

5 [0033] The two distinct dosage units and the time interval recommended between ingestion of the distinct dosage units will of course be the domain of those of skill in the art and may afford variations. The two distinct dosage units and recommended time intervals between ingestion is primarily aimed at minimizing known or eventual vitamin-vitamin, vitamin-mineral and mineral-mineral deleterious interactions.

10 [0034] An added benefit of the two distinct dosage units is the possibility for a patient to discontinue taking the type of dosage unit causing unwanted side effects while continuing with the other type of dosage unit.

15 [0035] An added benefit of the two distinct dosage units is the possibility for the manufacturer to produce a smaller and more palatable dosage unit, which improves patient compliance when compared to unpalatable large dosage units. The possibility for the manufacturer to produce smaller units is not only related to the fractionating of a daily dose into two dosage units but also because of the reduction of ingredient interactions which caused manufacturers to use greater quantities of ill-absorbed ingredients.

20 [0036] More specifically, in the most preferred embodiment of the invention, the calcium and iron ingredients are placed in distinct and different dosage units so as to avoid their known propensity to mutually interfere with their absorption.

[0037] Also in a most preferred embodiment, the folic acid and iron ingredients are placed in distinct and different dosage units so as to allow

discontinuance of the iron-containing dosage unit while maintaining ingestion of the folic acid-containing dosage unit.

[0038] Also in a most preferred embodiment, the amount of zinc present in the micronutrient supplement of the present invention, has been
5 reduced in order to further improve the iron bioavailability.

[0039] Furthermore, the presently disclosed micronutrient supplement comprises a greater iron/vitamin C ratio (1:3.4), further improving iron bioavailability.

[0040] In a most preferred and convenient embodiment, the
10 micronutrient supplement of the present invention will be provided with instructions to take a first type of dosage unit in the morning and a second type of dosage unit in the evening. In a most preferred embodiment, the folic acid ingredient will be present in the evening dosage unit while the iron ingredient will be present in the morning dosage unit. In cases where a patient suffers
15 from constipation as a result of the iron supplement, the patient would be able to halt the morning unit while continuing to take the important evening unit comprising folic acid. It is indeed of interest that patients have enough folic acid in their bodies given its potential prophylactic affect against certain types of cancers, heart disease, depression and for preventing certain types of birth
20 defects.

[0041] Thus the present invention provides a micronutrient supplement formulation having distinct dosage units to be taken at spaced apart time intervals. Most conveniently, one type of dosage unit can be taken in the morning and the second type in the evening. Hence, the AM and PM
25 formulations contain different ingredients. Each set of ingredients is aimed at

providing optimal nutritional components and amounts, while concurrently minimizing the undesired problems of the conventional unitary formulations.

[0042] In a preferred embodiment, the micronutrient supplement of the present invention will feature an AM dosage unit composition comprising:
5 provitamin A (beta-carotene), vitamin E (di- α -tocopheryl acetate), vitamin C (ascorbic acid), vitamin B₁ (thiamine mononitrate), vitamin B₂ (riboflavin), vitamin B₃ (niacinamide), vitamin B₆ (pyridoxine HCl), vitamin B₅ pantothenic acid (calcium pantothenate), magnesium (magnesium oxide), iodine (potassium iodide), iron (ferrous fumarate), copper (cupric oxide), zinc (zinc oxide), and
10 pharmaceutically acceptable excipients;

[0043] and the PM dosage unit composition will comprise: vitamin D₃ (cholecalciferol), vitamin B₁₂ (cyanocobalamin), folic acid, calcium (calcium carbonate) and pharmaceutically acceptable excipients.

[0044] Description of various preferred ingredients in best mode

15 **[0045]** When referring to quantities of preferred ingredients reference is made to quantities of pure substance regardless of form. For example, when referring to quantities of calcium or iron, reference is made to elemental calcium and elemental iron as opposed to quantities of calcium carbonate and ferrous fumarate. It is to be understood that adequate quantities
20 of calcium carbonate and ferrous fumarate would be used to contain the chosen amount of elemental calcium or iron.

[0046] Throughout this disclosure, when referring to the term about, was is to be understood is a variation of plus or minus 20%wt.

[0047] Beta-carotene or provitamin A is a precursor to vitamin A. Beta carotene is a potent antioxidant that appears to work synergistically with several vitamins, minerals and antioxidants. Beta-carotene is provided in the present micronutrient formulation in amounts of about 250 to 5000 I.U.; and
5 most preferably about 2700 I.U.

[0048] Vitamin B₁ (thiamine mononitrate) is an essential water-soluble B-vitamin playing an important role in the metabolism of carbohydrates. It is critical for the transmission of high-frequency impulses in the central nervous system. Vitamin B₁ is provided in the present micronutrient
10 formulation in amounts of about 0.5 to 10 mg; most preferably about 3.0 mg.

[0049] Vitamin B₂ (riboflavin) is an essential water-soluble B-vitamin that is required for the repair and growth of tissues as well as for DNA synthesis. It also assists in the metabolism of nutrients. Vitamin B₂ is provided in the present micronutrient formulation in amounts of about 0.5 to 10 mg and
15 most preferably about 3.4 mg.

[0050] Vitamin B₃ (niacinamide) is the amide form of the vitamin Niacine, and is an essential constituent of coenzymes I and II, occurring in a wide variety of enzyme systems, and which are involved in the anaerobic oxidation of carbohydrates. Vitamin B₃ is provided in the present micronutrient
20 formulation in amounts of about 2 to 50 mg and most preferably about 20.0 mg.

[0051] Vitamin B₆ (Pyridoxine HCl) is a term commonly used for a group of vitamins consisting of pyridoxine, pyridoxal, pyridoxal-5-phosphate, pyridoxamine, and pyridoxamine-5-phosphate. These vitamins are important in protein and amino acid metabolism and are required to synthesize hemoglobin.

Vitamin B₆ is provided in the present micronutrient formulation in amounts of about 2 to 100 mg and most preferably about 10.0 mg.

[0052] Vitamin B₁₂ (cyanocobalamine) is an essential water-soluble B vitamin that is provided in the present micronutrient formulation in amounts
5 of about 2 to 50 mcg and most preferably about 12.0 mcg.

[0053] Folic acid is a water soluble B-vitamin that helps build healthy cells. Folic acid is necessary for the synthesis of RNA and DNA. Folic acid is provided in the present micronutrient formulation in amounts of about 0.1 to 10 mg and most preferably about 1.1 mg. Since folic acid is water soluble, it is
10 readily eliminated from the body, and therefore has to be taken daily to help prevent, for example, neural tube defects in the fetus. During periods of rapid growth, such as during pregnancy and fetal development, the body's requirement for this vitamin increases. Patients having enough folic acid in their bodies can decrease the risk of some types of cancers, heart disease and even
15 depression. The U.S. Public Health Service currently recommends 400 micrograms of folic acid every day.

[0054] Vitamin B₅ Pantothenic acid (calcium pantothenate) is a water-soluble vitamin that plays an active role in the metabolism of proteins, fats and carbohydrates. It is also involved in the synthesis of sterols, hormones,
20 porphyrins and acetylcholine. Pantothenic acid is provided in the present micronutrient formulation in amounts of about 0.5 to 20 mg and most preferably about 5.0 mg.

[0055] Pharmaceutically acceptable forms of certain of the B vitamins include, but are not limited to, thiamine mononitrate or thiamine
25 hydrochloride, niacin or niacinamide; and pyridoxine hydrochloride.

[0056] Vitamin C (ascorbic acid) is an essential water-soluble vitamin that functions as an antioxidant. It is critical in producing and maintaining collagen and promotes wound healing. It is also important in producing hormones that regulate basal metabolic rate and body temperature.

5 Vitamin C (ascorbic acid) is provided in the present micronutrient formulation in amounts of about 10 to 1000 mg and most preferably about 120.0 mg. Pharmaceutically acceptable salts of ascorbic acid include, but are not limited to sodium or calcium ascorbate.

[0057] Vitamin D₃ (cholecalciferol) is an essential fat-soluble vitamin

10 whose major biological function is to maintain normal blood levels of calcium and phosphorus. Vitamin D₃ is provided in the present micronutrient formulation in amounts of about 10 to 1000 I.U. and most preferably about 250.0 I.U. vitamin D₃ (cholecalciferol). The vitamin D₃ used in the present formulation can include any of the forms of vitamin D that is a precursor to

15 cholecalciferol.

[0058] Vitamin E (dl- α -tocopheryl acetate) is a fat-soluble vitamin functioning as an antioxidant protecting lipid membranes from oxidation. Vitamin E (dl- α -tocopheryl acetate) is provided in the present micronutrient formulation in amounts of about 1 to 500 I.U. and most preferably about 30 I.U.

20 Vitamin E can also be present as α , β -, γ -, or δ -tocopheryl, or as a mixture or as an isomer thereof, such as dl- α -tocopheryl acetate or α -tocopheryl acetate. Salts of vitamin E include, but are not limited to, an acetate, or acid succinate salt.

[0059] Calcium (calcium carbonate) is required for adequate bone

25 formation and maintenance, as well as for diverse metabolic functions. Calcium is involved in the transmission of nerve impulses, muscle contraction and

relaxation, blood clotting, structure and function of cell membranes and vitamin B₁₂ absorption. Women are advised to increase their calcium intake substantially during pregnancy. Calcium is provided in the present micronutrient formulation in amounts of about 10 to 1500 mg and most preferably about 5 300.0 mg, in the form of suitable amounts of calcium carbonate to equate to the required amount of calcium. Calcium carbonate relies on stomach acid to dissolve. Supplemental calcium is beneficial for the skeletal system.

[0060] Iron (ferrous fumarate) is an essential mineral playing an important role in the transport of oxygen to tissues throughout the body via 10 hemoglobin and myoglobin. Iron is provided in the present micronutrient formulation in the form of ferrous fumarate, corresponding to amounts of elemental iron of about 2 to 300 mg and most preferably about 35 mg.

[0061] Magnesium (magnesium oxide) is an essential mineral for many biological processes. Magnesium is provided in the present micronutrient 15 formulation in the form of magnesium oxide, in amounts of about 5 to 200 mg and most preferably about 50 mg. Magnesium can be incorporated in the present micronutrient formulation in various forms such as an oxide, a sulfate, or the like.

[0062] Zinc (zinc oxide) is a trace mineral essential to cell 20 multiplication, tissue regeneration and wound healing. It is required in many enzymatic functions throughout the body, and also helps regulate the immune system and insulin metabolism. Zinc is provided in the present micronutrient formulation in the form of zinc oxide, in amounts of about 1 to 50 mg and most preferably about 15 mg. Zinc can be incorporated in the present formulation in 25 various forms such as an oxide, a phosphate, a chloride, a sulfate, a nitrate, a gluconate, or the like, as well as metallic zinc.

[0063] Copper (cuprous oxide) is a trace mineral essential for red blood cell formation. Copper is provided in the present micronutrient formulation in the form of cupric oxide, in amounts of about 0.5 to 10 mg and most preferably about 2.0 mg. Copper can be incorporated in the present
5 micronutrient formulation in various forms such as a sulfate, a nitrate, a chloride, a carbonate, an oxide, a hydroxide, an iodide, a glutamate, an aspartate, a citrate, or the like.

[0064] Iodine (potassium iodide) is essential for proper thyroid functioning. Iodine is provided in the present micronutrient formulation in the
10 form of a potassium salt, wherein the iodine is present in amounts of about 0.05 to 1 mg and most preferably about 0.15 mg.

[0065] The vitamins and minerals and other nutritional aids incorporated in the micronutrient of the present invention are of food-grade, approved for use in humans (U.S. Pharmacopoeia); they may be obtained from
15 various distributors known to one of skill in the art.

[0066] Further micronutrients, including but not limited to vitamin A, vitamin K, fatty acids (including linoleic acid, linolenic acid, and omega-3 fatty acids), phosphorous, selenium, boron, biotin, choline, inositol, chromium, molybdenum, cobalt, fluorine, manganese, nickel, potassium, or the like, may
20 be added to the micronutrient formulation of the present invention, provided they do not interfere with the components already described.

[0067] The micronutrient formulation of the present invention preferably contains the active ingredients described above, and may contain non-active excipients such as for example fillers or binders, disintegrating
25 agents, lubricating agents, silica flow conditioners and stabilizing agents.

[0068] Disintegrating agents are included in the present formulation to assist in the dissolution of the tablet. Disintegrating agents are well known in the art and include, but are not limited to alginic acid, carboxymethylcellulose, carboxymethylcellulose sodium, hydroxypropylcellulose (low substituted),
5 microcrystalline cellulose, powdered cellulose, colloidal silicon dioxide, sodium croscarmellose, crospovidone, methylcellulose, polacrillin potassium, povidone, sodium alginate, sodium starch glycolate, starch, disodium disulfite, disodium edathamil, disodium edetate, disodiummethylenediaminetetraacetate (EDTA), crosslinked polyvinylpyrrolidines, pregelatinized starch, carboxymethyl starch,
10 sodium carboxymethylstarch, microcrystalline cellulose. A preferred disintegrating agent consists of sodium croscarmellose, and is provided in the present dosage unit formulation in amounts of about 2 to 100 mg preferably about 30 to 40 mg.

[0069] Lubricating agents are included in the present formulation to
15 assist in the compression of the formulation. Lubricating agents are well known in the art and include, but are not limited to calcium stearate, canola oil, glyceryl palmitostearate, hydrogenated vegetable oil (type I), magnesium oxide, magnesium stearate, mineral oil, poloxamer, polyethylene glycols, sodium lauryl sulfate, sodium stearate fumarate, stearic acid, talc, zinc stearate,
20 glyceryl behapate, magnesium lauryl sulfate, boric acid, sodium benzoate, sodium acetate, sodium benzoate/sodium acetate (in combination) and D,L-leucine. Preferred lubricants consists of magnesium stearate and sodium lauryl sulfate and are provided in the present AM multi-vitamin formulation in amounts of about 1 to 20 mg and most preferably equal amounts of about 3 to 4 mg.

25 **[0070]** Fillers or binders well known in the art, are included in the present formulation and include, but are not limited to acacia, alginic acid, calcium phosphate (dibasic), carboxymethylcellulose, carboxymethylcellulose

sodium, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, dextrin, dextrates, sucrose, tylose, pregelatinized starch, calcium sulfate, amylose, glycine, bentonite, maltose, sorbitol, ethylcellulose, disodium hydrogen phosphate, disodium phosphate, 5 disodium pyrosulfite, polyvinyl alcohol, gelatin, glucose, guar gum, liquid glucose, compressible sugar, magnesium aluminum silicate, maltodextrin, polyethylene oxide, polymethacrylates, povidone, sodium alginate, microcrystalline cellulose, starch and zein. Preferred fillers or binders consists of microcrystalline cellulose and starch, and are provided in the present 10 morning dosage unit in amounts of 10 to 500mg and most preferably about 180 mg and 55 mg respectively.

[0071] Many other pharmaceutically acceptable tableting agents such as fillers or binders, lubricating agents, disintegrating agents, silica flow conditioners and stabilizing agents known in the pharmaceutical arts can be 15 used in the formulation and tableting of the micronutrient formulation of the present invention (see, e.g. Remington: *The Science and Practice of Pharmacy and Handbook of Pharmaceutical Excipients*; Kibbe: *Handbook of Pharmaceutical Excipients*). As used herein, pharmaceutically acceptable is any agent suitable for use in humans without undue side effects, such as 20 irritation, toxicity, or allergic response.

Example 1**[0072]**

The following is an example of a morning dosage unit core formulation:

Table 1: Core ingredients:

Item #	Ingredient	Label Claim	mg/Tab.
1.	Beta Carotene	2700 IU	
2.	Vitamin E	30 IU	
3.	Vitamin C	120mg	
4.	Vitamin B ₁	3mg	
5.	Vitamin B ₂	3.4mg	
6.	Vitamin B ₃	20mg	
7.	Vitamin B ₆	10mg	
8.	Pantothenic Acid	5mg	
9.	Magnesium	50mg	
10.	Iodine	0.15mg	
11.	Iron	35mg	
12.	Copper	2mg	
13.	Zinc	15mg	
14.	Cross carmellose Sodium		35
15.	Sodium Lauryl Sulphate		3.5
16.	Microcrystalline Cellulose PH102		180
17.	Starch 1500		55
18.	Magnesium Stearate		3.5

5

[0073]

The following is an example of an evening dosage unit core formulation:

Table 2: Core ingredients:

Item #	Ingredient	Label Claim	Mg/Tab.
1.	Vitamin D ₃	250IU	
2.	Calcium	300mg	
3.	Vitamin B ₁₂	12mcg	
4.	Folic Acid	1.1mg	
5.	Cross carmellose Sodium		30
6.	Sodium Lauryl Sulfate		3
7.	Magnesium Stearate		3

Dispensing Kit

5 [0074] Referring now to Figure 1, the product of the present invention may be conveniently marketed as a dispensing kit containing distinct dosage units grouped by type. Blister packs [10] of a week's worth of the supplement of the present invention having an array [12] of a first type of dosage unit to be taken at a given time of day and an array [14] of a second type of dosage unit to be taken at another time of day. Conveniently, 5 blister packs can be grouped in a
 10 box (not shown) for sale as monthly dosage packs. Advantageously, the package of dosage units will contain a 30 day supply, as four 7-day blister packs and one 2-day blister pack.

15 [0075] In the case of pregnant women or those wishing to become pregnant, Ideally, a woman expecting to become pregnant may start taking the multivitamin and mineral supplement of the present invention at least three months prior to pregnancy, thereafter during the entire pregnancy and during a postpartum period of at least three months.

[0076] Still referring to Figure 1, the blister pack includes graphical means [16] and [18] permitting a patient to differentiate between the morning and evening dosage types. These means may be, for example, a color code or diagrams surrounding a particular array of dosage units of the same type be it
5 morning or evening.

[0077] Another benefit of the blister pack is that micronutrient supplements often have an unpleasant odor. By providing a "blister pack", each tablet is confined to its individual blister, significantly reducing odor emanations.

[0078] The cores of the formulations of the present invention are
10 preferably coated to achieve a chosen wear resistance, aesthetic appearance, external finish or dissolution profile. Enteric, seal or color coats can be used. This may be accomplished by tablet coating procedures well known to those skilled in the pharmaceutical arts, such as for example pan coating or spray coating.

15 **[0079]** In a most preferred embodiment, the morning dosage unit of the present invention is provided with a sprayed-on Opadry Pink™ coating and polished with carnauba wax to avoid sticking. Still in a most preferred embodiment the evening dosage unit is provided with a sprayed-on Opadry Blue™ coating and also polished with carnauba wax.

20 **[0080]** It is to be understood that although a preferred embodiment of the invention is in the form of oral tablets, other dosage units and routes of administration could be used such as sublingual, rectal, intravenous, topical, etc.

[0081] Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified without departing from the spirit and nature of the subject invention as defined in the appended claims.

WHAT IS CLAIMED IS:

1. A micronutrient supplement, the supplement being characterized by having at least two types of distinct dosage units wherein said distinct dosage units physically separate micronutrients which are known or proven to be negatively interacting when co-mingled or co-administered, said distinct dosage units being designed to be taken at a predetermined time interval.
2. The supplement of claim 1 wherein the time interval is at least four hours.
3. The supplement of claim 1 wherein the time interval is 8 to 12 hours.
4. The supplement of claim 1 wherein micronutrients that are known to potentially cause deleterious side effects are grouped in a separate and distinct dosage unit.
5. The supplement of claim 1 wherein iron is essentially provided in a first dosage unit and calcium is essentially provided in a second dosage unit.
6. A micronutrient supplement, said supplement comprising a first dosage unit type and an second dosage unit type, the first dosage unit type comprises:
 - (a) from about 250 to about 5000 I.U. of beta-carotene;
 - (b) from about 0.5 to about 10 mg of vitamin B₁, preferably present in thiamine mononitrate;
 - (c) from about 0.5 to about 10 mg of vitamin B₂, preferably present in riboflavin;
 - (d) from about 2 to about 50 mg of vitamin B₃, preferably present in niacinamide;

- (e) from about 2 to about 100 mg of vitamin B₆, preferably present pyridoxine HCl;
- (f) from about 0.5 to about 20 mg of pantothenic acid, preferably present in calcium pantothenate;
- 5 (g) from about 10 to about 1000 mg of vitamin C, preferably present in ascorbic acid
- (h) from about 1 to about 500 I.U. of vitamin E, preferably present in dl- α -tocopheryl acetate;
- 10 (i) from about 2 to about 300 mg of iron, preferably present in ferrous fumarate;
- (j) from about 1 to about 50 mg of zinc, preferably present in zinc oxide;
- (k) from about 0.5 to about 10 mg of copper, preferably present in cupric oxide;
- 15 (l) from about 5 to about 200 mg of magnesium, preferably present in magnesium oxide; and
- (m) from about 0.05 to about 1 mg of iodine, preferably present in potassium iodide;
- and wherein the second dosage unit type comprises:
- 20 (a) from about 10 to about 1000 I.U. of vitamin D₃, preferably present in cholecalciferol;
- (b) from about 2 to about 50 mcg of vitamin B₁₂, preferably present in cyanocobalamine;
- (c) from about 0.1 to about 10 mg of folic acid; and
- 25 (d) from about 10 to about 1500 mg of calcium, preferably present in calcium carbonate.

7. A micronutrient supplement, said supplement comprising a first dosage
A micronutrient supplement according to claim 6, said supplement
comprising a first dosage unit type and an second dosage unit type, the
first dosage unit type comprises:
- 5 a) about 2700 I.U. of betacarotene;
b) about 3 mg of vitamin B₁, present in thiamine mononitrate;
c) about 3.4 mg of vitamin B₂, present in riboflavin;
d) about 20 mg of vitamin B₃, present in niacinamide;
e) about 10 mg of vitamin B₆, present pyridoxine HCl;
10 f) about 5 mg of pantothenic acid, present in calcium pantothenate;
g) about 120 mg of vitamin C, present in ascorbic acid
h) about 30 I.U. of vitamin E, present in dl- α -tocopheryl acetate;
i) about 35 mg of iron, present in ferrous fumarate;
j) about 15 mg of zinc, present in zinc oxide;
15 k) about 2 mg of copper, present in cupric oxide;
l) about 50 mg of magnesium, present in magnesium oxide; and
m) about 0.15 mg of iodine, present in potassium iodide;
- and wherein the second dosage unit type comprises:
- 20 a) about 250 I.U. of vitamin D₃, present in cholecalciferol;
b) about 12 mcg of vitamin B₁₂, present in cyanocobalamine;
c) about 1.1 mg of folic acid; and
d) about 300 mg of a calcium, present in calcium carbonate.
8. A method of treating or preventing a micronutrient deficiency, comprising
25 administering a therapeutically effective amount of the micronutrient
supplement of claim 1 to a patient in need thereof.

9. A micronutrient supplement dispensing kit, said kit comprising a plurality of foil-sealed blister cavities wherein each blister cavity comprises a dosage unit, said blister packages comprising an array of blisters containing dosage units of a first type and an array of blisters containing dosage units of a second type, said kit further comprising dosage regimen instructions including information on the recommended time of day for taking a dosage unit of a first type and a dosage unit of a second type.
10. The kit of claim 9 wherein the first type of dosage unit is color-coded and the second type of dosage unit is color-coded.
11. The kit of claim 10 wherein the first type of dosage unit is color-coded pink and the dosage regimen instructions include a recommendation to ingest the pink dosage unit in the morning.
12. The kit of claim 11 wherein the second type of dosage unit is color-coded blue and the dosage regimen instructions include a recommendation to ingest the blue dosage unit in the evening.
13. The kit of claim 12 wherein the array of blisters of pink dosage units consists of seven blisters corresponding to the days of the week.
14. The kit of claim 13 wherein the array of blisters of blue dosage units consists of seven blisters corresponding to the days of the week.
15. The kit of claim 14 wherein the array are provided on separate flaps of a unitary blister support substrate which contains a week's worth of pink and blue dosage units.

16. The kit of claim 15 wherein the kit is in the form of box containing a plurality of blister support substrates so as to contain about a monthly supply of pink and blue dosage units.
- 5 17. A pregnancy micronutrient supplement suitable for prenatal and postpartum use, the supplement being characterized by having at least two types of distinct dosage units wherein said distinct dosage units physically separate micronutrients which are known or proven to be negatively interacting when co-mingled or co-administered, said distinct dosage units being designed to be taken at a predetermined time
10 interval.
18. The supplement of claim 17 wherein the time interval is at least four hours.
19. The supplement of claim 17 wherein the time interval is 8 to 12 hours.
- 15 20. The supplement of claim 17 wherein micronutrient supplements which are known to potentially cause deleterious side effects are grouped in a separate and distinct dosage unit.
21. The supplement of claim 17 wherein iron is essentially provided in a first dosage unit and calcium is essentially provided in a second dosage unit.
- 20 22. A pregnancy micronutrient supplement suitable for prenatal and postpartum use, said supplement comprising a first dosage unit type and an second dosage unit type, the first dosage unit type comprises:
- a) from about 250 to about 5000 I.U. of beta-carotene;
 - b) from about 0.5 to about 10 mg of vitamin B₁, preferably present in thiamine mononitrate;

- c) from about 0.5 to about 10 mg of vitamin B₂, preferably present in riboflavin;
- d) from about 2 to about 50 mg of vitamin B₃, preferably present in niacinamide;
- 5 e) from about 2 to about 100 mg of vitamin B₆, preferably present in pyridoxine HCl;
- f) from about 0.5 to about 20 mg of pantothenic acid, preferably present in calcium pantothenate;
- 10 g) from about 10 to about 1000 mg of vitamin C, preferably present in ascorbic acid;
- h) from about 1 to about 500 I.U. of vitamin E, preferably present in dl- α -tocopheryl acetate;
- i) from about 2 to about 300 mg of iron, preferably present in ferrous fumarate;
- 15 j) from about 1 to about 50 mg of zinc, preferably present in zinc oxide;
- k) from about 0.5 to about 10 mg of copper, preferably present in cupric oxide;
- l) from about 5 to about 200 mg of magnesium, preferably present in magnesium oxide; and
- 20 m) from about 0.05 to about 1 mg of iodine, preferably present in potassium iodide

and wherein the second dosage unit type comprises:

- a) from about 10 to about 1000 I.U. of vitamin D₃, preferably present in cholecalciferol;
- 25 b) from about 2 to about 50 mcg of vitamin B₁₂, preferably present in cyanocobalamine;
- c) from about 0.1 to about 10 mg of folic acid; and

d) from about 10 to about 1500 mg of calcium, preferably present in calcium carbonate.

23. A pregnancy micronutrient according to claim 22, said supplement
5 comprising a first dosage unit type and an second dosage unit type, the first dosage unit type comprises:

- a) about 2700 I.U. of betacarotene;
- b) about 3 mg of vitamin B₁, present in thiamine mononitrate;
- c) about 3.4 mg of vitamin B₂, present in riboflavin;
- 10 d) about 20 mg of vitamin B₃, present in niacinamide;
- e) about 10 mg of vitamin B₆, present in pyridoxine HCl;
- f) about 5 mg of pantothenic acid, present in calcium pantothenate;
- g) about 120 mg of vitamin C, present in ascorbic acid;
- h) about 30 I.U. of vitamin E, present in dl- α -tocopheryl acetate;
- 15 i) about 35 mg of iron, present in ferrous fumarate;
- j) about 15 mg of zinc, present in zinc oxide;
- k) about 2 mg of copper, present in cupric oxide;
- l) about 50 mg of magnesium, present in magnesium oxide; and
- m) about 0.15 mg of iodine, present in potassium iodide;

20 and wherein the second dosage unit type comprises:

- a) about 250 I.U. of vitamin D₃, present in cholecalciferol;
- b) about 12 mcg of vitamin B₁₂, present in cyanocobalamine;
- c) about 1.1 mg of folic acid; and
- d) about 300 mg of calcium, present in calcium carbonate.


25

24. A method of treating or preventing a micronutrient deficiency, comprising administering a therapeutically effective amount of the micronutrient supplement of claim 17 to a pregnant woman in need thereof.

25. A prenatal and postpartum micronutrient supplement dispensing kit, said kit comprising a plurality of foil-sealed blister cavities wherein each blister cavity comprises a dosage unit, said blister packages comprising an array of blisters containing dosage units of a first type and an array of blisters containing dosage units of a second type, said kit further comprising dosage regimen instructions including information on the recommended time of day for taking a dosage unit of a first type and a dosage unit of a second type.
26. The kit of claim 25 wherein the first type of dosage unit is color-coded and the second type of dosage unit is color-coded.
27. The kit of claim 26 wherein the first type of dosage unit is color-coded pink and the dosage regimen instructions include a recommendation to ingest the pink dosage unit in the morning.
28. The kit of claim 27 wherein the second type of dosage unit is color-coded blue and the dosage regimen instructions include a recommendation to ingest the blue dosage unit in the evening.
29. The kit of claim 28 wherein the array of blisters of pink dosage units consists of seven blisters corresponding to the days of the week.
30. The kit of claim 29 wherein the array of blisters of blue dosage units consists of seven blisters corresponding to the days of the week.
31. The kit of claim 30 wherein the array are provided on separate flaps of a unitary blister support substrate which contains a week's worth of pink and blue dosage units.

31

32. The kit of claim 31 wherein the kit is in the form of box containing a plurality of blister support substrates so as to contain about a montly supply of pink and blue dosage units.



INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/001533

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 A61K-33/34, A23L-1/302, C07G-13/00, B65D-75/36, A61P-3/02, A61K-45/06

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC7 A61K, A23L, C07G, B65D, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base, and, where practicable, search terms used)
Pubmed, Delphion, Canadian Patent Database (CPD), EPOLINE, USPTO; Techsource, Internet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Seligman et al., Measurements of iron absorption from prenatal multivitamin-mineral supplements, Obstet. Gynecol. 61, 1983, pp 356-362. Abstract and Table 1.	1-5, 17-21
Y	US 4431634 (Ellenbogen) 14 February 1984 (14.02.1984). Col. 1-2 and example 1.	1-5, 17-21
Y	US 4752479 (Briggs et al) 21 June 1988 (21.06.1988). Col 1, lines. 24-51; col. 1, line 65 - col. 2, lines 1-7 and col. 3-4.	1-5, 17-21
Y	Campbell et al., Iron supplements: a common cause of drug interactions, J. clin Pharmac. 31, 1991, pp 251-255. Abstract and Table 1.	1-5, 17-21
Y	US 5932624 (Herbert) 3 August 1999 (03.08.1999). Col.1, lines 54-59; col. 3, lines 12-51.	1-5, 17-21
Y	US 5976568 (Riley) 2 October 1999 (02.11.1999). Abstract, col. 10, lines 46-55; col. 11, lines 8-62 and claims 1-5.	1-5, 17-21
Y	US 6214379B1 (Hermelin) 10 April 2001 (10.04.2001) Abstract; col. 5, lines 33-46, col. 7, lines 30-54, col. 15, lines 12-15 and claims 15-16.	1-5, 17-21

Further documents are listed in the continuation of Box C.

Patent family members are listed in annex.

* Special categories of cited documents :	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international-type search

26 November 2004 (26-11-2004)26

Date of mailing of the international-type search report

07 January 2005 (07-01-2005)

Name and mailing address of the ISA/CA

Commissioner of Patents
Canadian Patent Office - PCT
Ottawa/Gatineau KIA 0C9

Authorized officer

Maja Solajic (819) 956-4121

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/001533

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Recommended Dietary Allowances, 10th ed., National Academic Press, Washington, D.C. 1989, pp 283. Page 1, 2 nd paragraph and attached table on p. 285.	6-8, 22-24
Y	GB 2212722A (Kemeny et al.) 2 August 1989 (02.08.1989) Abstract and claims 1-3.	6-8, 22-24
Y	WO 95/35098 (Paradissis et al.) 28 December 1995 (28.12.1995). Page 3, line 11- page 6 line 20; page.9, lines 17-37 and page10, lines 4-11.	6-8, 22-24
Y	CA 2064959 (Rea et al.) 2 April 1992 02.04.1992 Abstract, page 3 line 11 - page 4, line 3; page 9, lines 11-19; page 9, line 31-page 10, line 4 and drawing figures 2 & 5.	9-16, 25-32
Y	CA 1155427 (Knudsen) 18 October 1983 (18.10.1983) Abstract and drawing figure 1.	9-16, 25-32
A	CA 2378378A1 (Hermelin & Kirschner) 21 February 2001 (21.02.2001) Whole document.	9-16, 25-32
A	US 5788974 (D'Amico & Maida) 4 August 1988 (04.08.1988) Whole document.	9-16, 25-32

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/CA2004/001533**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. ☒ Claims Nos. : 8 and 24
because they relate to subject matter not required to be searched by this Authority; namely:

Although claims 8 and 24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :
3. ☐ Claims Nos. :
because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observation where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos. :
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. :

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2004/001533

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US4431634	14-02-1984	NONE	
US4752479	21-06-1988	AU597064 B2 AU7338987 A BE1000434 A5 CA1300012 C CH671515 A5 DE3717543 A1 DK163279B B FR2601589 A1 GB2196847 A IT1206286 B JP62283928 A LU86887 A1 NL8701259 A NZ220447 A PH24219 A SE466287 B SE8702180 A US4752479 A ZA8703775 A	24-05-1990 03-12-1987 06-12-1988 05-05-1992 15-09-1989 03-12-1987 17-02-1992 22-01-1988 11-05-1988 14-04-1989 09-12-1987 13-06-1988 16-12-1987 27-03-1990 10-04-1990 27-01-1992 28-11-1987 21-06-1988 27-11-1987
US5932624	03-08-1999	CA2234954 A1 EP0859619 A1 US5932624 A US6265391 B1 US6605646 B2 US2001029252 A1 WO9714422 A1	24-04-1997 26-08-1998 03-08-1999 24-07-2001 12-08-2003 11-10-2001 24-04-1997
US5976568	02-11-1999	NONE	
US6214379	10-04-2001	AU3546899 A BR9909903 A CA2327068 A1 EP1067906 A1 JP2002510612T T US5945123 A US6214379 B1 US2004062802 A1 WO9951203 A1 ZA200005271 A	25-10-1999 26-12-2000 14-10-1999 17-01-2001 09-04-2002 31-08-1999 10-04-2001 01-04-2004 14-10-1999 01-08-2001
GB2212722	02-08-1989	NONE	
WO9535098	28-12-1995	AU2862295 A AU5252299 A AU7088400 A BR0016065 A CA2392184 A1 DE1235487T T1 EP1235487 A1 ES2183750T T1 US5869084 A US6352713 B1 US6488956 B1 US2002034543 A1 US2002187205 A1 US2003068372 A1 WO0007463 A1 WO0139601 A1 WO9535098 A1	15-01-1996 28-02-2000 12-06-2001 27-05-2003 07-06-2001 10-04-2003 04-09-2002 01-04-2003 09-02-1999 05-03-2002 03-12-2002 21-03-2002 12-12-2002 10-04-2003 17-02-2000 07-06-2001 28-12-1995
CA2064959	03-10-1993	NONE	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/001533

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
CA1155427	18-10-1983	AU5263879 A	14-05-1981
		BE879918 A1	08-05-1980
		CA1155427 A1	18-10-1983
		CH641668 A5	15-03-1984
		DE2945355 A1	22-05-1980
		ES256592U U	01-10-1981
		FR2440736 A1	06-06-1980
		GB2037164 A	09-07-1980
		IE49112 B1	07-08-1985
		IL58649 A	30-04-1982
		IT1126825 B	21-05-1986
		IT7923092V V0	12-11-1979
		JP55086461 A	30-06-1980
		US4295567 A	20-10-1981
		ZA7905999 A	29-10-1980
CA2378378	21-02-2001	AU5780100 A	13-02-2001
		BR0013173 A	02-04-2002
		CA2378378 A1	21-02-2001
		DE1207850T T1	09-01-2003
		EP1207850 A1	29-05-2002
		ES2182729T T1	16-03-2003
		JP2003505154T T	12-02-2003
		MXPA02000806 A	22-07-2002
		US6375956 B1	23-04-2002
		WO0107012 A1	01-02-2001
US5788974	04-08-1998	NONE	